Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-20260425215446_20260426-210416",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Response: Microglial Senescence in ALS—Translational Assessment\n\n## Preliminary Note on Framing\n\nThe original debate and your questions contain an artifact: the framing references Alzheimer's clinical landscape, but the research question concerns ALS. I'll answer the substance of your questions applied to ALS, as that is where the mechanistic debate is situated. The translational logic—evaluating hypotheses against patient population fit, existing trial infrastructure, and validated endpoints—transfers directly.\n\n---\n\n## 1. Highest Translational Potential Hypotheses\n\n### Hypothesis 1 (Highest Priority): SASP Factor Secretion and Neurotoxicity via Specific Cytokine Targeting\n\n**Why it leads:**\n\n- The causal chain is mechanistically specific and targetable at multiple nodes (IL-6, TNF-α, CCL2, IL-1β)\n- Current clinical infrastructure for cytokine inhibition already exists in ALS trials: **Biogen's BIIB061** (anti-IL6R),",
  "tokens_used": "237"
}